Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.40
AFFX's Cash to Debt is ranked higher than
50% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. AFFX: 0.40 )
AFFX' s 10-Year Cash to Debt Range
Min: 0.19   Max: 15.67
Current: 0.4

0.19
15.67
Equity to Asset 0.54
AFFX's Equity to Asset is ranked higher than
55% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. AFFX: 0.54 )
AFFX' s 10-Year Equity to Asset Range
Min: 0.22   Max: 0.95
Current: 0.54

0.22
0.95
F-Score: 3
Z-Score: 0.49
M-Score: -3.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3.80
AFFX's Operating margin (%) is ranked higher than
65% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. AFFX: -3.80 )
AFFX' s 10-Year Operating margin (%) Range
Min: -254.35   Max: 17.26
Current: -3.8

-254.35
17.26
Net-margin (%) -4.94
AFFX's Net-margin (%) is ranked higher than
62% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. AFFX: -4.94 )
AFFX' s 10-Year Net-margin (%) Range
Min: -232.61   Max: 17.9
Current: -4.94

-232.61
17.9
ROE (%) -6.01
AFFX's ROE (%) is ranked higher than
64% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. AFFX: -6.01 )
AFFX' s 10-Year ROE (%) Range
Min: -101.4   Max: 19.11
Current: -6.01

-101.4
19.11
ROA (%) -3.24
AFFX's ROA (%) is ranked higher than
65% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. AFFX: -3.24 )
AFFX' s 10-Year ROA (%) Range
Min: -43.17   Max: 9.53
Current: -3.24

-43.17
9.53
ROC (Joel Greenblatt) (%) -17.17
AFFX's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. AFFX: -17.17 )
AFFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -166.29   Max: 70.53
Current: -17.17

-166.29
70.53
Revenue Growth (%) 0.80
AFFX's Revenue Growth (%) is ranked higher than
66% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. AFFX: 0.80 )
AFFX' s 10-Year Revenue Growth (%) Range
Min: -33.6   Max: 102.9
Current: 0.8

-33.6
102.9
EPS Growth (%) 15.30
AFFX's EPS Growth (%) is ranked higher than
85% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. AFFX: 15.30 )
AFFX' s 10-Year EPS Growth (%) Range
Min: -55.3   Max: 25.1
Current: 15.3

-55.3
25.1
» AFFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

AFFX Guru Trades in Q1 2013

Murray Stahl 104,000 sh (unchged)
Chuck Royce 150,000 sh (unchged)
PRIMECAP Management 6,681,740 sh (-4.42%)
» More
Q2 2013

AFFX Guru Trades in Q2 2013

Chuck Royce 150,000 sh (unchged)
Murray Stahl 104,000 sh (unchged)
PRIMECAP Management 6,616,740 sh (-0.97%)
» More
Q3 2013

AFFX Guru Trades in Q3 2013

Joel Greenblatt 268,084 sh (New)
Jim Simons 410,400 sh (New)
Paul Tudor Jones 47,200 sh (New)
PRIMECAP Management 8,134,440 sh (+22.94%)
Chuck Royce 150,000 sh (unchged)
Murray Stahl 104,000 sh (unchged)
» More
Q4 2013

AFFX Guru Trades in Q4 2013

Jim Simons 1,032,500 sh (+151.58%)
PRIMECAP Management 10,666,640 sh (+31.13%)
Paul Tudor Jones 48,674 sh (+3.12%)
Murray Stahl 104,000 sh (unchged)
Chuck Royce 130,000 sh (-13.33%)
Joel Greenblatt 31,187 sh (-88.37%)
» More
» Details

Insider Trades

Latest Guru Trades with AFFX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Reduce -88.37%0.05%$6.35 - $8.85 $ 7.2-6%31187
PRIMECAP Management 2013-12-31 Add 31.13%0.03%$6.35 - $8.85 $ 7.2-6%10666640
Joel Greenblatt 2013-09-30 New Buy0.05%$3.78 - $6.3 $ 7.240%268084
PRIMECAP Management 2013-09-30 Add 22.94%0.01%$3.78 - $6.3 $ 7.240%8134440
Joel Greenblatt 2012-09-30 Sold Out 0.06%$3.61 - $4.7 $ 7.273%0
Joel Greenblatt 2012-06-30 Reduce -50.63%0.07%$4.01 - $5.11 $ 7.256%175755
PRIMECAP Management 2012-06-30 Add 149.79%0.03%$4.01 - $5.11 $ 7.256%7025440
Joel Greenblatt 2012-03-31 Add 67.73%0.05%$4.11 - $5.21 $ 7.272%356011
Joel Greenblatt 2011-12-31 Add 92.44%0.05%$3.7 - $5.83 $ 7.251%212251
Joel Greenblatt 2011-09-30 New Buy0.09%$4.14 - $8 $ 7.229%110294
Joel Greenblatt 2011-06-30 Sold Out 0.02%$5.01 - $7.85 $ 7.214%0
Joel Greenblatt 2011-03-31 New Buy0.02%$4.45 - $5.53 $ 7.245%15174
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
AFFX's P/B is ranked higher than
85% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. AFFX: 1.80 )
AFFX' s 10-Year P/B Range
Min: 0.24   Max: 12.23
Current: 1.8

0.24
12.23
P/S 1.60
AFFX's P/S is ranked higher than
81% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. AFFX: 1.60 )
AFFX' s 10-Year P/S Range
Min: 0.38   Max: 11.22
Current: 1.6

0.38
11.22
PFCF 10.70
AFFX's PFCF is ranked higher than
92% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.36 vs. AFFX: 10.70 )
AFFX' s 10-Year PFCF Range
Min: 1.89   Max: 1220.5
Current: 10.7

1.89
1220.5
EV-to-EBIT 142.90
AFFX's EV-to-EBIT is ranked lower than
82% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. AFFX: 142.90 )
AFFX' s 10-Year EV-to-EBIT Range
Min: 0.3   Max: 836.3
Current: 142.9

0.3
836.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.00
AFFX's Price/DCF (Projected) is ranked higher than
91% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. AFFX: 1.00 )
AFFX' s 10-Year Price/DCF (Projected) Range
Min: 0.42   Max: 26.68
Current: 1

0.42
26.68
Price/Median PS Value 0.90
AFFX's Price/Median PS Value is ranked higher than
87% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. AFFX: 0.90 )
AFFX' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 21.98
Current: 0.9

0.3
21.98
Earnings Yield (Greenblatt) 0.70
AFFX's Earnings Yield (Greenblatt) is ranked lower than
68% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. AFFX: 0.70 )
AFFX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 387
Current: 0.7

0.1
387
Forward Rate of Return (Yacktman) 2.62
AFFX's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. AFFX: 2.62 )
AFFX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -18.5   Max: 2.3
Current: 2.62

-18.5
2.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AFF.Germany
Affymetrix, Inc., was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Company's operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. In addition, the business units share common corporate services that provide capital, infrastructure and functional support, allowing them to focus on core technological strengths to compete and innovate in their markets. The three business units that form Affymetrix Core are: Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents.Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications: This business unit develops and markets the Company's genotyping, such as the Axiom product line and arrays with clinical research applications, such as the CytoScan cytogenetics arrays; Life Science Reagents: This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience: This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Company's operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide